HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease.

Abstract
Dipyridamole has been shown to decrease proteinuria and improve renal function progression especially in early chronic kidney disease (CKD) patients with glomerulonephropathy. A combination therapy of dipyridamole with aspirin could prevent second strokes in the general population. Whether these effects of dipyridamole are also true in advanced CKD patients and whether dipyridamole could improve renal outcomes or patient survival is unknown. We retrospectively analyzed an observational cohort of 3074 participants with CKD stage 3-5 from southern Taiwan, of whom 871 (28.3%) had received dipyridamole treatment ≥50 mg/d for ≥3 months and more than half of the observation period. The mean age was 63.6 ± 13.4 years and the mean estimated glomerular filtration rate (eGFR) was 25.5 mL/min/1.73 m(2). After inverse probability of treatment weighted adjustment by propensity score, there were no differences between the dipyridamole-treated and untreated groups. Dipyridamole treatment was associated with decreased odds for rapid eGFR decline [odds ratio, 0.755; 95% confidence interval (CI), 0.595-0.958; p = 0.007] and progression of urine protein-to-creatinine ratio (odds ratio, 0.655; 95% CI, 0.517-0.832; p = 0.002). In survival analysis, the dipyridamole-treated group was also associated with a decreased risk for end-stage renal disease (hazard ratio, 0.847; 95% CI, 0.733-0.980; p = 0.011) and all-cause mortality (hazard ratio, 0.765; 95% CI, 0.606-0.971; p = 0.001) but not for cardiovascular events. Our findings demonstrate that dipyridamole treatment is significantly associated with better renal outcomes and patient survival in patients with CKD stage 3-5. Further investigations are warranted to confirm these independent positive effects.
AuthorsChi-Chih Hung, Mei-Li Yang, Ming-Yen Lin, Hugo You-Hsien Lin, Lee-Moay Lim, Hung-Tien Kuo, Shang-Jyh Hwang, Jer-Chia Tsai, Hung-Chun Chen
JournalThe Kaohsiung journal of medical sciences (Kaohsiung J Med Sci) Vol. 30 Issue 12 Pg. 599-607 (Dec 2014) ISSN: 2410-8650 [Electronic] China (Republic : 1949- )
PMID25476097 (Publication Type: Journal Article)
CopyrightCopyright © 2014. Published by Elsevier Taiwan.
Chemical References
  • Dipyridamole
  • Creatinine
Topics
  • Creatinine (urine)
  • Demography
  • Dipyridamole (therapeutic use)
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney Failure, Chronic (drug therapy)
  • Logistic Models
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Renal Insufficiency, Chronic (drug therapy, mortality, physiopathology, urine)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: